Vera Therapeutics, Inc. (VERA): debt financing — Vera Therapeutics enters up to $500M loan facility with Oxford Finance; $75M initial draw

Vera Therapeutics, Inc.

Initial $75M funded June 4, 2025; remaining $50M from $125M first tranche drawable in 2026.
Additional tranches: up to $175M upon milestones, plus $200M uncommitted subject to mutual agreement.
Interest rate: greater of 1-Month Term SOFR + 4.95% and 8.70%; maturity June 2030 or 2031.
Collateral on substantially all assets except IP; financial covenants require minimum liquidity or loan coverage ratios.
Facility fee 0.75% of funded amount; final payment and prepayment fees apply.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Vera Therapeutics, Inc. incurred credit facility of up to $500.0 million with Oxford Finance LLC at greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70% maturing June 1, 2030, or June 1, 2031.

Instrument: credit facility
Principal: up to $500.0 million
Counterparty: Oxford Finance LLC
Rate: greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70%
Maturity: June 1, 2030, or June 1, 2031
Event: incurrence

Exact text from the filing

On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million.

View on SEC.gov

34 debt financings filed in the last 30 days. Browse all debt financings →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-133730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.